Veracyte
Veracyte is a company that provides diagnostic tests for various cancers and interstitial lung disease, aiming to improve patient care and treatment decisions through genomic classifiers and noninvasive tools.
Services Offered by Veracyte
Veracyte offers diagnostic tests for several types of cancers and interstitial lung disease (ILD). The cancers include thyroid, prostate, lung, breast, and bladder cancer. These tests are designed to help patients avoid unnecessary surgeries, inform treatment decisions, and improve diagnostic confidence. Some of Veracyte's notable tests include the Afirma Genomic Sequencing Classifier for thyroid nodules, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, Envisia Genomic Classifier for ILD, Decipher Bladder Genomic Classifier, and Percepta Nasal Swab test for lung cancer risk assessment.
Key Products from Veracyte
Veracyte's key products are known for their innovative genomic analysis capabilities. These include the Afirma Genomic Sequencing Classifier for thyroid nodules, which helps patients avoid unnecessary diagnostic surgeries. The Decipher Prostate Genomic Classifier is widely validated and helps in treatment decision-making for localized prostate cancer. The company also offers the Prosigna Breast Cancer Assay, included in leading international clinical guidelines, and the Envisia Genomic Classifier for ILD, which helps improve diagnostic and prognostic confidence. Additionally, the Decipher Bladder Genomic Classifier utilizes whole-transcriptome analysis to classify bladder tumors into molecular subtypes, and the Percepta Nasal Swab test is a noninvasive tool for assessing lung cancer risk.
Veracyte's Global Presence
Veracyte has established offices in multiple locations around the world to extend its services globally. These offices are located in South San Francisco, CA; San Diego, CA; Austin, TX; Marseille, France; and Haifa, Israel. The company's diagnostic tests are available in the United States through their central laboratories and are increasingly being made accessible to patients worldwide through partnerships with other laboratories.
Collaborations and Clinical Impact
Veracyte collaborates closely with clinicians and scientists to identify unmet needs and develop solutions that enhance patient care. The company's tests have been utilized by over 400,000 patients, addressing cancers that affect more than 7 million people globally each year. Notable collaborations have led to the extensive validation of tests such as the Decipher Prostate Genomic Classifier in over 75 peer-reviewed studies involving nearly 110,000 patients.